Company Analysis
Sign in

aTyr Pharma, Inc. (ATYR)

Nasdaq: ATYR · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2005
Full chart Alerts Compare
Grade3.7
◀ Past 2.4● Present 4.8▶ Future 3.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

93 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to aTyr Pharma, Inc.’s names, not what it holds today.

Patents granted
93
93 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 1 in 2024 and 2 in 2023
Applications published
127
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals10
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
aTyr Pharma, Inc. its own name
US, as the owner printed on each patent
93 granted
39 published
aTyr Pharma, Inc. its own name
named as the applicant on its applications, in US
0 granted
88 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 16, 202512,497,466Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activitiesPharmaceuticalsaTyr Pharma, Inc.
Dec 9, 202512,492,392Histidyl-tRNA synthetase-Fc conjugates and therapeutics using the samePharmaceuticalsaTyr Pharma, Inc.
Sep 9, 202512,410,253Compositions comprising anti-NRP2 antibodiesPharmaceuticalsaTyr Pharma, Inc.
Aug 20, 202412,065,495Compositions and methods comprising anti-NRP2 antibodiesPharmaceuticalsaTyr Pharma, Inc.
Nov 7, 202311,807,687Therapeutic compositions comprising anti-NRP2 antibodiesPharmaceuticalsaTyr Pharma, Inc.
Sep 26, 202311,767,520Compositions and methods for treating lung inflammationPharmaceuticalsaTyr Pharma, Inc.
Nov 22, 202211,505,610Compositions and methods comprising anti-NRP2 antibodiesPharmaceuticalsaTyr Pharma, Inc.
Aug 3, 202111,078,299Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activitiesPharmaceuticalsaTyr Pharma, Inc.
Jul 27, 202111,072,787Histidyl-tRNA synthetase-Fc conjugatesPharmaceuticalsaTyr Pharma, Inc.
Mar 9, 202110,941,214Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activitiesPharmaceuticalsaTyr Pharma, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 3, 20252025/0216395COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIESAnalysis of biological materialsaTyr Pharma, Inc.
Jun 12, 20252025/0188170COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2b ANTIBODIESAnalysis of biological materialsaTyr Pharma, Inc.
Mar 6, 20252025/0074990COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIESPharmaceuticalsaTyr Pharma, Inc.
Dec 19, 20242024/0417476COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIESAnalysis of biological materialsaTyr Pharma, Inc.
Mar 21, 20242024/0092917COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIESPharmaceuticalsaTyr Pharma, Inc. · patent 12,410,253 granted from it
Oct 5, 20232023/0312730COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIESPharmaceuticalsaTyr Pharma, Inc. · patent 12,065,495 granted from it
Feb 9, 20232023/0039401COMPOSITIONS AND METHODS FOR TREATING NRP2-ASSOCIATED DISEASESPharmaceuticalsaTyr Pharma, Inc.
Mar 31, 20222022/0098568HISTIDYL-TRNA SYNTHETASE-FC CONJUGATESPharmaceuticalsaTyr Pharma, Inc. · patent 12,492,392 granted from it
Mar 31, 20222022/0098327COMPOSITIONS AND METHODS COMPRISING HISTIDYL-TRNA SYNTHETASE SPLICE VARIANTS HAVING NON-CANONICAL BIOLOGICAL ACTIVITIESPharmaceuticalsaTyr Pharma, Inc. · patent 12,497,466 granted from it
Jun 3, 20212021/0163606COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIESPharmaceuticalsaTyr Pharma, Inc. · patent 11,807,687 granted from it
What it applied for, 2024 to 2025: Analysis of biological materials 3 · Pharmaceuticals 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ATYR · research, not advice